Assessing differential application of thromboprophylaxis regimes related to risk of pulmonary embolism and mortality in COVID-19 patients through instrumental variable analysis

Thrombotic complications are common in Coronavirus disease 2019 (COVID-19) patients, with pulmonary embolism (PE) being the most frequent. Randomised trials have provided inconclusive results on the optimal dosage of thromboprophylaxis in critically ill COVID-19 patients. We utilized data from the multicentre CAPACITY-COVID patient registry to assess the effect of differential application of Low Molecular Weight Heparin (LMWH) dose protocols on PE and in-hospital mortality risk in critically ill COVID-19 patients. An instrumental variable analysis was performed to estimate the intention-to-treat effect, utilizing differences in thromboprophylaxis prescribing behaviour between hospitals. We included 939 patients with PCR confirmed SARS-CoV-2 infection from 34 hospitals. Two-hundred-and-one patients (21%) developed a PE. The adjusted cause-specific HR of PE was 0.92 (95% CI: 0.73-1.16) per doubling of LMWH dose. The adjusted cause-specific HR for in-hospital mortality was 0.82 (95% CI: 0.65-1.02) per doubling of LMWH dose. This dose-response relationship was shown to be non-linear. To conclude, this study did not find evidence for an effect of LMWH dose on the risk of PE, but suggested a non-linear decreased risk of in-hospital mortality for higher doses of LMWH. However, uncertainty remains, and the dose-response relationship between LMWH dose and in-hospital mortality needs further investigation in well-designed studies.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-03-25
DOI
https://doi.org/10.1038/s41598-024-77858-w
Citations
1
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
1.40

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Assessing differential application of thromboprophylaxis regimes related to risk of pulmonary embolism and mortality in COVID-19 patients through instrumental variable analysis

Saskia Middeldorp, Hans‐Marc J. Siebelink, Michiel Coppens, Frank W.G. Leebeek et al.
1 citations
Scientific Reports
COVID-19 Clinical Research Studies
1.40
article

Assessing differential application of thromboprophylaxis regimes related to risk of pulmonary embolism and mortality in COVID-19 patients through instrumental variable analysis

Saskia Middeldorp, Hans‐Marc J. Siebelink, Michiel Coppens, Frank W.G. Leebeek, Evert de Jonge, Koen S. Simons, Wiek H. van Gilst, Y.L. Soei, Linda Nab, R. A. Tio, Marthe S. Paats, Gaby Captur, Matthijs C. Brouwer, Thomas Langerak, Eric Wierda, Josep Redón, Fleur H.J. Kaptein, Marion Koopmans, Johannes G. Krabbe, Sabrina H. van Ierssel, Willem M. Lijfering, L. Nieuwenhuizen, Paul L. den Exter, Sytze de Bruin, Fleur S. Kleijwegt, Lisa Hessels, Eline A. Vlot, Rolf T. Urbanus, Behnam Hedayat, Renske H. Olie, P. H. M. Westendorp, Richard Bruggeman, Tilman M. Hackeng, Massimo Caputo, Coen Maas, Roel Vink, S.R.S. Ramai, M. I. A. Ribeiro, Mettine H.A. Bos, P. M. van der Zee, Jeroen C.J. Eikenboom, Esther G.M. De Waal, Firdaouss Boutkourt, Mark T. Kearney, Pim van der Harst, Leon M. van den Toorn, Barry Rockx, Jan Berg, Daan J.L. van Twist, Marijke Linschoten, H. E. Haerkens-Arends, P. S. Monraats, Kirby Tong‐Minh, Mathilde Nijkeuter, Laurence Gabriël, Cees M.P.M. Hertogh, Esther J. Nossent, Matthias Kant, Suzanne C. Cannegieter, Carolina A. M. Schurink, Rosa Macías‐Ruiz, Kristien Winckers, Anton Vonk Noordegraaf, A. M. Alshehri, Chantal Visser, L. S. D. Jewbali, Iris C.D. Westendorp, Menno V. Huisman, Elias Hellou, Gerry P McCann, H. P. A. A. van Veen, Emeline M. Van Craenenbroeck, Remy H.H. Bemelmans, B. Williams, F. J. H. Magdelijns, Marlies E. Kevenaar, Jan Westerink, Johan De Sutter, Bas Franken, Barbara Festen, Y. A. Almubarak, Pier Woudstra, Hugo Ten Cate, Derk O. Verschure, Arina J. ten Cate‐Hoek, Eric C. M. Van Gorp, D. J. van de Watering, Danny Noack, Thijs F. van Haaps, Marcel M.C. Hovens, R. S. Hermanides, N. Charlotte, Paul M Dark, Dirk J. van der Heijden, Jacqueline G. Hugtenburg, Mohammed Alshahrani, Elena Tessitore, Ruben Bierings, Yvo M. Smulders, Caroline Weytjens, Henri H. Versteeg, J.J. Miranda Geelhoed, Bart J.M. van Vlijmen, Philippe Timmermans, Brigitte Westerhof, Evelien Oostdijk, Corstiaan A. den Uil, J. Burggraaf, Arend Mosterd, Ilse M. Schrover, Tom W. van de Berg, Astrid Schut, Henrik Endeman, P.R. Nierop, Eva K Kempers, C. E. Delsing, Moniek P.M. de Maat, Johanna M. Kwakkel‐van Erp, Rolf E. Brouwer, Leo Heunks, Akbar Shafiee, Todd Kuiken, Bart Spaetgens, Stefanie Koster, Cornelis P. C. de Jager, Coen van Guldener, Maartje van den Biggelaar, Casper Rokx, Bas C. T. van Bussel, Janise Braga Barros Ferreira, Laura Montagna, Frederikus Albertus Klok, Pim van der Meer, G. C. M. Linssen, Ron Pisters, Kees Kramers, Janine van Kooten, F. Nanne Croles, Swati Prasad, Roger E. G. Schutgens, Pieter Roel Tuinman, Robert G Tieleman, Manish Saxena, Y M Pinto, Nick van Es, Anna H.E. Roukens, J.F. Hermans-van Ast, A G Zaman, Peter Smits, Clara E E van Ofwegen-Hanekamp, Stéphane Heymans, A. J. M. van Boxem, Marco Goeijenbier, Daniek A. M. Meijs, Maarten van Smeden, Harald J. Faber, Annie Cornet, Karina Meijer, Susanne Stads, Anne‐Marije Hulshof, Nicole Hunfeld, Mandy N. Lauw, Leon J. Schurgers, E. Saneei, Jan Voorberg, Bas de Laat, M. M. J. M. van der Linden, Lianne R. de Haan, Angela C. Shore, R. L. Anthonio, Alexander P. J. Vlaar, Henri M.H. Spronk, Albertus Beishuizen, Hein Putter, I. van der Lee, Ton Lisman, Mark J R Smeets, Rehab Salah, Fabrice M A C Martens, Marten R. Nijziel, Jeroen van den Akker, Yvonne Henskens, Brigitte M. Sondermeijer, Nuray Kuşadasi, Chang-Han Jong, Saskia le Cessie, Lucia J.M. Kroft, Fahd A Al-Muhanna, Evert‐Jan Wils, Pieter W. Kamphuisen, B. E. Groenemeijer, Mathijs Raadsen, A. N. Alnafie, Araci M. R. Rondon, P. Y. Kopylov, Avinash Aujayeb, H. A. H. Kaasjager, Janneke Tijmensen, Jeroen K. de Vries, H. A. M. van Kesteren, M. W. J. van Hessen, Pim van Montfort, Amein K. Al‐Ali, Milou A.M. Stals, Nicole P. Juffermans, Fleur V.Y. Tjong, Bas Kietselaer, Marije ten Wolde, Hamidreza Poorhosseini, Gideon R. Hajer, Mireille E. Emans, Olaf L. Cremer, A. C. Reidinga, Diederik A M P J Gommers, Marcella C.A. Müller, Marieke J.H.A. Kruip, Diederik van de Beek, Peter Messiaen, J. Leentjes, A. Stemerdink, A. Lansbergen, David P Ripley, Mark M. G. Mulder, Hubert W. Vliegen, I. C. C. van der Horst, Y.I.G. van Tichelaar, Renée A. Douma, Geert-Jan Geersing, Wim Boersma, A. Moriarty, M.K. Ninaber, Ruben Zaal, Marco J.J.H. Grootenboers, J. T. Drost, Jacobien Ellerbroek, K. W. Wu, Folkert W Asselbergs, Thiemo Veneman, Jeroen Schaap, Dirk Schellings, R. M. A. van de Wal, M. F. L. Meijs, N. Y. Y. Al-Windy, Bram van den Borst, J. C. M. Meijers, M. Louisa Antoni, Thirza J. Roest, Aafke M H Koning, Joyce Faber, Frank Stam, H. G. R. Dorman, Laura M. Faber, A. F. M. Kuijper
article en
1 citations

Abstract

Thrombotic complications are common in Coronavirus disease 2019 (COVID-19) patients, with pulmonary embolism (PE) being the most frequent. Randomised trials have provided inconclusive results on the optimal dosage of thromboprophylaxis in critically ill COVID-19 patients. We utilized data from the multicentre CAPACITY-COVID patient registry to assess the effect of differential application of Low Molecular Weight Heparin (LMWH) dose protocols on PE and in-hospital mortality risk in critically ill COVID-19 patients. An instrumental variable analysis was performed to estimate the intention-to-treat effect, utilizing differences in thromboprophylaxis prescribing behaviour between hospitals. We included 939 patients with PCR confirmed SARS-CoV-2 infection from 34 hospitals. Two-hundred-and-one patients (21%) developed a PE. The adjusted cause-specific HR of PE was 0.92 (95% CI: 0.73-1.16) per doubling of LMWH dose. The adjusted cause-specific HR for in-hospital mortality was 0.82 (95% CI: 0.65-1.02) per doubling of LMWH dose. This dose-response relationship was shown to be non-linear. To conclude, this study did not find evidence for an effect of LMWH dose on the risk of PE, but suggested a non-linear decreased risk of in-hospital mortality for higher doses of LMWH. However, uncertainty remains, and the dose-response relationship between LMWH dose and in-hospital mortality needs further investigation in well-designed studies.

Scientific ReportsVol. 15(1)
Leiden University (NL), Saint-Gobain (France) (FR), University of Leeds (GB), University Medical Center Groningen (NL), Radboud University Nijmegen (NL), University of Antwerp (BE), University of Leicester (GB), Universitat de València (ES), Queen Mary University of London (GB), Royal Free London NHS Foundation Trust (GB), University of Groningen (NL), Sechenov University (RU), Utrecht University (NL), Benha University (EG), University of Exeter (GB), Nazareth Hospital EMMS (IL), Leiden University Medical Center (NL), Maastricht University Medical Centre (NL), University Hospitals Bristol NHS Foundation Trust (GB), Gelre Hospitals (NL), Northumbria Healthcare NHS Foundation Trust (GB), Salford Royal NHS Foundation Trust (GB), Catharina Ziekenhuis (NL), Royal Devon and Exeter Hospital (GB), King Fahd Hospital of the University (SA), Newcastle upon Tyne Hospitals NHS Foundation Trust (GB), Medisch Spectrum Twente (NL), Freeman Hospital (GB), Erasmus MC (NL), Glenfield Hospital (GB), Medisch Centrum Leeuwarden (NL), Radboud University Medical Center (NL), University Medical Center Utrecht (NL), Sanquin (NL), Ghent University (BE), Maastricht University (NL), National Institute for Health and Care Research (GB), University of Bristol (GB), Sint Franciscus Gasthuis (NL), Noordwest Ziekenhuisgroep (NL), Albert Schweitzer Ziekenhuis (NL), VIB-KU Leuven Center for Cancer Biology (BE), Slingeland Ziekenhuis (NL), Jessa Hospital (BE), Rode Kruis Ziekenhuis (NL), Royal Brompton Hospital (GB), Medisch Centrum Haaglanden (NL), Reinier de Graaf Hospital (NL), Hospital Prof. Dr. Fernando Fonseca (PT), Northwest Hospital (US), Antwerp University Hospital (BE), Werkgroep Cardiologische centra Nederland (NL), St. Antonius Ziekenhuis (NL), Ikazia Ziekenhuis (NL), Netherlands Heart Institute (NL), Amphia Ziekenhuis (NL), University Hospital of Geneva (CH), Diakonessenhuis hospital (NL), Amsterdam Neuroscience (NL), Maasstad Ziekenhuis (NL), Hospital do Espírito Santo (PT), Treant Zorggroep (NL), Martini Ziekenhuis (NL), Lange Land Ziekenhuis (NL), Hospital Universitario Virgen de las Nieves (ES), Beatrix Kinderziekenhuis (NL), Ziekenhuis Bethesda (NL), Ziekenhuis Gelderse Vallei (NL), Máxima Medisch Centrum (NL), Zaans Medisch Centrum (NL), NIHR Exeter Clinical Research Facility (GB), Synapse (Netherlands) (NL), Zuyderland Medisch Centrum (NL), Groene Hart Ziekenhuis (NL), AZ Maria Middelares (BE), Ziekenhuis Amstelland (NL), Isala (NL), Tergooi (NL), Federatie Medisch Specialisten (NL), Elisabeth-TweeSteden Ziekenhuis (NL), Ziekenhuis Groep Twente (NL), Erasmus MC Cancer Institute (NL), William Harvey Research Institute (GB), Franciscus Vlietland (NL), Admiraal De Ruyter Ziekenhuis (NL), Amsterdam University Medical Centers (NL), Rijnstate Hospital (NL), Ospedale San Luigi Gonzaga (IT), Deventer Ziekenhuis (NL), Ziekenhuis Bernhoven (NL), Medisch Centrum Alkmaar (NL), INCLIVA Health Research Institute (ES), Meander Medisch Centrum (NL), Jeroen Bosch Ziekenhuis (NL), Bravis Ziekenhuis (NL), Spaarne Gasthuis (NL), University Hospitals Bristol and Weston NHS Foundation Trust (GB), University College London (GB), Imperial College London (GB), Tehran University of Medical Sciences (IR), Imam Abdulrahman Bin Faisal University (SA), Newcastle University (GB), Vrije Universiteit Amsterdam (NL), Hasselt University (BE), University of Amsterdam (NL), Erasmus University Rotterdam (NL), UCLouvain (BE)
Sanofi, Alexion Pharmaceuticals, CSL Behring, Society for Cardiovascular Magnetic Resonance, Dutch Cardiovascular Alliance, National Institute for Health and Care Research, British Heart Foundation, University College London, European Society of Cardiology, ZonMw, Novo Nordisk, EuroQol Research Foundation, Servier, Trombosestichting Nederland, Swedish Orphan Biovitrum, InflaRx, Sanofi Genzyme, Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 23%
COVID-19 Clinical Research Studies
1.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.